US stock · Healthcare sector · Biotechnology
Company Logo

Apellis Pharmaceuticals, Inc.

APLSNASDAQ

58.32

USD
-2.77
(-4.53%)
Market Closed
-9.74P/E
-12Forward P/E
-0.49P/E to S&P500
6.407BMarket CAP
- -Div Yield
Scale: |
View:
Currency: USD, in millions
2013
2014
2015
2016
2017
2018
2019
2020
2021
Income Statement
Revenue
- -
- -
- -
- -
- -
- -
- -
251
67
COGS
- -
- -
- -
- -
- -
- -
- -
25
5
Gross Profit
- -
- -
- -
- -
- -
- -
- -
226
61
Gross Profit Ratio
- -
- -
- -
- -
- -
- -
- -
90.01%
92.19%
Operating Expenses
4
11
20
27
51
128
288
439
598
R&D Expenses
2
8
14
23
40
105
221
300
421
Selling, G&A Exp.
2
3
6
4
10
23
67
139
177
General and Admin. Exp.
2
3
6
4
10
23
67
139
177
Selling and Marketing Exp.
- -
- -
- -
- -
- -
- -
- -
- -
- -
Other Expenses
- -
- -
- -
- -
- -
- -
- -
- -
- -
COGS and Expenses
4
11
20
27
51
128
288
464
603
Interest Income
- -
- -
- -
- -
- -
3
5
4
0
Interest Expense
- -
- -
- -
- -
- -
3
5
30
13
Depreciation and Amortization
0
0
- -
- -
0
- -
0
1
1
EBITDA
(4)
(11)
6
(27)
(51)
(125)
(288)
(312)
(731)
EBITDA ratio
(Infinity)%
(Infinity)%
Infinity%
(Infinity)%
(Infinity)%
(Infinity)%
(Infinity)%
(124.66)%
(1,098.61)%
Operating Income
(4)
(11)
(47)
(27)
(51)
(128)
(288)
(214)
(536)
Operating Income ratio
(Infinity)%
(Infinity)%
(Infinity)%
(Infinity)%
(Infinity)%
(Infinity)%
(Infinity)%
(85.27)%
(805.67)%
Total Other Income Exp.(Gains)
0
0
0
0
(0)
0
(17)
(129)
(210)
Income Before Tax
(4)
(11)
(47)
(27)
(51)
(128)
(305)
(343)
(746)
Income Before Tax ratio
(Infinity)%
(Infinity)%
(Infinity)%
(Infinity)%
(Infinity)%
(Infinity)%
(Infinity)%
(136.86)%
(1,120.75)%
Income Tax Expense (Gain)
- -
(0)
- -
- -
- -
- -
- -
2
0
Net Income
(4)
(11)
(47)
(27)
(51)
(128)
(305)
(345)
(746)
Net Income Ratio
(Infinity)%
(Infinity)%
(Infinity)%
(Infinity)%
(Infinity)%
(Infinity)%
(Infinity)%
(137.59)%
(1,121.27)%
EPS
(0.22)
(0.60)
(2.57)
(1.51)
(3.68)
(2.34)
(4.90)
(4.59)
(8.84)
EPS Diluted
(0.22)
(0.60)
(2.57)
(1.51)
(3.68)
(2.34)
(4.90)
(4.59)
(8.84)
Weighted Avg. Shares Outs.
18
18
18
18
14
54
62
75
75
Weighted Avg. Shares Outs. Dil.
18
18
18
18
14
54
62
75
75
Balance Sheet
Cash and Cash Equivalents
5
14
36
25
176
176
352
566
640
Short-Term Investments
- -
- -
- -
- -
- -
- -
- -
312
60
Cash & Short-Term Investments
5
14
36
25
176
176
352
878
701
Net Receivables
0
0
- -
- -
- -
- -
- -
- -
10
Inventory
- -
- -
- -
- -
- -
- -
- -
- -
16
Other Current Assets
0
0
2
3
6
26
21
40
97
Total Current Assets
5
14
38
27
182
202
373
917
824
PP&E
0
0
- -
- -
- -
- -
16
25
26
Goodwill
- -
- -
- -
- -
- -
- -
- -
- -
- -
Intangible Assets
- -
- -
- -
- -
- -
- -
- -
- -
- -
Goodwill and Intangible Assets
- -
- -
- -
- -
- -
- -
- -
- -
- -
Investments
- -
- -
- -
- -
- -
- -
- -
- -
- -
Tax Assets
- -
- -
- -
- -
- -
- -
- -
- -
- -
Other Non-Current Assets
- -
0
0
0
0
1
0
19
32
Total Non-Current Assets
0
0
0
0
0
1
16
43
58
Other Assets
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Assets
5
14
38
27
182
204
389
961
882
Accounts Payable
0
1
2
3
4
10
8
8
17
Short-Term Debt
- -
- -
- -
- -
- -
2
3
4
4
Tax Payable
- -
- -
- -
- -
- -
- -
- -
- -
- -
Deferred Revenue
- -
- -
- -
- -
- -
- -
- -
- -
- -
Other Current Liabilities
0
0
1
1
3
5
55
116
111
Total Current Liabilities
1
1
3
4
7
17
66
128
132
Long-Term Debt
- -
- -
- -
- -
26
25
143
359
206
Deferred Revenue
- -
- -
- -
- -
- -
- -
- -
- -
- -
Deferred Tax Liabilities
- -
- -
- -
- -
- -
- -
- -
- -
- -
Other Non-Current Liabilities
- -
- -
- -
- -
0
0
147
269
345
Total Non-Current Liabilities
- -
- -
- -
- -
27
26
289
628
551
Other Liabilities
- -
- -
- -
- -
- -
- -
- -
- -
- -
Capital Lease Obligations
- -
- -
- -
- -
- -
- -
14
19
21
Total Liabilities
1
1
3
4
33
43
355
756
683
Preferred Stock
17
36
77
92
- -
- -
- -
- -
- -
Common Stock
0
0
0
0
0
0
0
0
0
Retained Earnings
(14)
(25)
(71)
(98)
(149)
(277)
(581)
(926)
(1,657)
Other Compreh. Income(Loss)
(0)
(0)
- -
- -
- -
(0)
(0)
(0)
(2)
Other Total Stockhold. Equity
2
2
29
30
298
438
616
1,131
1,857
Total Stockholders Equity
5
13
35
24
149
161
34
205
199
Total Liab.&Stockhold. Equity
5
14
38
27
182
204
389
961
882
Minority Interest
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Liabilities & Equity
5
14
38
27
182
204
389
961
882
Cash Flow Statement
Net Income
(4)
(11)
(47)
(27)
(51)
(128)
(305)
(345)
(746)
Depreciation and Amortization
0
0
- -
- -
0
- -
0
1
1
Deferred Income Tax
- -
- -
- -
- -
- -
- -
- -
- -
- -
Stock Based Compensation
0
1
1
1
5
8
21
45
71
Change in Working Capital
0
0
1
0
(1)
(12)
53
20
(94)
Accounts Receivable
- -
- -
- -
- -
- -
- -
- -
- -
(10)
Inventory
- -
- -
- -
- -
- -
- -
- -
- -
(16)
Accounts Payable
0
0
2
0
1
7
(2)
(0)
10
Other Working Capital
5
(0)
(0)
0
(0)
(1)
(0)
(18)
- -
Other Non-Cash Items
- -
0
26
- -
0
1
19
119
205
Cash Provided by Operating Activities
(3)
(10)
(19)
(26)
(47)
(131)
(211)
(160)
(563)
CAPEX
- -
(0)
- -
- -
- -
- -
(2)
(5)
(1)
Acquisitions Net
- -
- -
- -
- -
- -
- -
- -
- -
- -
Purchases of Investments
- -
- -
- -
- -
- -
- -
- -
(879)
(171)
Sales/Maturities of Investments
- -
- -
- -
- -
- -
- -
- -
568
420
Other Investing Activities
- -
- -
- -
- -
- -
- -
- -
- -
- -
Cash Used for Investing Activities
- -
(0)
- -
- -
- -
- -
(2)
(317)
248
Debt Repayment
(0)
- -
- -
- -
- -
- -
(29)
- -
- -
Common Stock Issued
- -
- -
0
- -
150
131
110
381
380
Common Stock Repurchased
- -
- -
- -
- -
- -
- -
- -
- -
3
Dividends Paid
- -
- -
- -
- -
- -
- -
- -
- -
- -
Other Financing Activities
7
19
41
15
47
1
308
311
9
Cash Used/Provided by Financing Activities
7
19
41
15
197
132
389
692
392
Effect of Forex Changes on Cash
- -
- -
- -
- -
- -
(0)
0
0
(2)
Net Change In Cash
4
9
22
(11)
151
1
176
215
75
Cash at the End of Period
5
14
36
25
176
176
352
567
642
Cash at the Beginning of Period
1
5
14
36
25
176
176
352
567
Free Cash Flow
(3)
(10)
(19)
(26)
(47)
(131)
(213)
(166)
(564)
Forex Rate
- -
- -
- -
- -
- -
- -
- -
- -
- -